Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13603959 | 0.86 | ALDH1A1 (0.67) | ALDH1A1POLBMAPTKMT2AMEN1 | |
| SCHEMBL11925367 | 0.85 | ALDH1A1 (0.78) | ALDH1A1POLBMAPTKMT2AMEN1 | |
| SCHEMBL1610031 | 0.82 | POLB (1.00) | ALDH1A1POLBMAPTKMT2AMEN1 | |
| SCHEMBL7992707 | 0.81 | POLB (0.97) | ALDH1A1POLBMAPTKMT2AMEN1 | |
| SCHEMBL10448232 | 0.80 | ALDH1A1 (1.00) | ALDH1A1POLBMAPTKMT2AMEN1 | |
| SCHEMBL8188675 | 0.79 | ALDH1A1 (0.72) | ALDH1A1POLBMAPTKMT2AMEN1 | |
| Silver SCHEMBL7992706 | 0.78 | ALDH1A1 (0.76) | ALDH1A1POLBMAPTKMT2AMEN1 | |
| SCHEMBL5592639 | 0.78 | ALDH1A1 (0.76) | ALDH1A1POLBMAPTKMT2AMEN1 | |
| SCHEMBL10998726 | 0.77 | ALDH1A1 (0.66) | ALDH1A1POLBMAPTKMT2AMEN1 | |
| SCHEMBL10970208 | 0.76 | ALDH1A1 (0.71) | ALDH1A1POLBMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163456-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-06-03 | — | — | US | disclosed |
| WO-2019199667-A2 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | KEANEY GREGG F (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163456-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | ALDH1A1 3225/4885POLB 1222/4885MAPT 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.